Examine conclusions offered at the virtual IDWeek 2020 meeting indicated that the COVID-19 pandemic did not lead to HIV treatment interruptions through the several world-wide trials assessing very long-acting cabotegravir and rilpivirine for Artwork.

In this exclusive MedPage Now online video, Monica Gandhi, MD, of UCSF/San Francisco General Clinic, discusses the worth of these analyze final results.

Subsequent is a transcript of her remarks:

This examine that was executed by ViiV that looked at the influence of the COVID pandemic on the long acting cabotegravir (Cab) and rilpivirine (RPV) dosing throughout the scientific trials. So in essence these are ongoing trials. There is certainly even now ongoing people who are obtaining cabotegravir and rilpivirine throughout the various trials. And the dilemma was, in the period III Aptitude examine and the ATLAS research has the worldwide COVID pandemic not only slowed down the enrollment and the continued visits for these individuals, but could there be a worry that people today were not coming in for the extended performing injectables? And so there could be failure in the context of these procedure trials with all the chaos surrounding COVID-19.

So essentially this certain research appeared at persons who have been still lively in the stage II and III Cab+RPV extended-acting clinical trials from December 1st, 2019, all the way up to September 2020. So spanning this time of COVID. And they seemed at data from 1,744 members. And they search specially at, were men and women equipped to occur in, were they in a position to get their injectable? And quite importantly, during these COVID-19 impacted visits, the analyze investigators presented oral bridges of Taxi+RPV at residence, if they could not occur in.

And so fundamentally what the bottom line of this review was that irrespective of all of these interruptions with the COVID pandemic, there have not been any Artwork interruptions in people 1,700 folks in the ongoing ViiV trials. And in point, most or 93% of those people injection visits transpired on time. And then the couple people today who really couldn’t arrive in for all those COVID-19 visits, they had the oral Cab+RPV as a bridge. And so they had been in a position to proceed that oral ARB bridge. And luckily there were no scenarios of neurologic failure through this time of COVID for these ongoing individuals in the demo.

So that was very reassuring facts from ViiV, and maybe giving us classes for thinking about the foreseeable future. That if we have key issues heading on in the planet that are likely to impression our injectables, how do we support notify how to retain on supplying persons injectables or oral bridges.

  • Greg Laub joined MedPage Today in 2005 as Generation Supervisor and led the launch of the video clip department in 2007. He is now dependable for the website’s online video creation. Follow